EGFR and colorectal cancer: Data from a systematic review of KRAS testing and response to treatment with EGFR inhibitors in patients with advanced colorectal cancer [4] reported that median OS was between 6.6 and 24.9 months for patients with wild-type KRAS, and 4.4 and 17.5 months for patients with mutated KRAS. Our median OS was between 15.3 and 21.5 months, depending on KRAS mutation status and pre- versus post-testing period.